Gemcitabine combined with capecitabine compared to gemcitabine with or without erlotinib as first-line chemotherapy in patients with advanced pancreatic cancer: Comparative effectiveness study.

被引：0
|
作者：
Cho, Jangho
Lim, Jae Yun
Cho, Jae Yong
机构：
[1] Gangnam Severance Hosp, Dept Med Oncol, Seoul, South Korea
[2] Gangnam Severance Hosp, Seoul, South Korea
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15132
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Gemcitabine-erlotinib versus gemcitabine-erlotinib-capecitabine in the first-line treatment of patients with metastatic pancreatic cancer: Efficacy and safety results of a phase IIb randomised study from the Spanish TTD Collaborative Group
    Irigoyen, Antonio
    Gallego, Javier
    Guillen Ponce, Carmen
    Vera, Ruth
    Iranzo, Vega
    Ales, Inmaculada
    Arevalo, Sara
    Pisa, Aleydis
    Martin, Marta
    Salud, Antonieta
    Falco, Esther
    Saenz, Alberto
    Manzano Mozo, Jose Luis
    Pulido, Gema
    Martinez Galan, Joaquina
    Pazo-Cid, Roberto
    Rivera, Fernando
    Garcia Garcia, Teresa
    Serra, Olbia
    Fernandez Parra, Eva Ma
    Hurtado, Alicia
    Gomez Reina, Ma Jose
    Lopez Gomez, Luis Jesus
    Martinez Ortega, Esther
    Benavides, Manuel
    Aranda, Enrique
    EUROPEAN JOURNAL OF CANCER, 2017, 75 : 73 - 82
  • [32] Sequential gemcitabine and platinum versus first-line combination of gemcitabine and platinum for advanced pancreatic cancer treatment: a retrospective study
    Guo, Jhe-Cyuan
    Yang, Shih-Hung
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2014, 19 (04) : 634 - 642
  • [33] Sequential gemcitabine and platinum versus first-line combination of gemcitabine and platinum for advanced pancreatic cancer treatment: a retrospective study
    Jhe-Cyuan Guo
    Shih-Hung Yang
    International Journal of Clinical Oncology, 2014, 19 : 634 - 642
  • [34] GEMCITABINE AND CAPECITABINE (GEMCAP) AS FIRST-LINE CHEMOTHERAPY IN ADVANCED BILIARY TRACT ADENOCARCINOMAS: RESULTS OF A PHASE II STUDY
    Rozzi, A.
    Corona, M.
    Nardoni, C.
    Restuccia, M.
    Falbo, T.
    Lanzetta, G.
    ANNALS OF ONCOLOGY, 2010, 21 : 102 - 102
  • [35] Patterns of Thromboembolism in Patients with Advanced Pancreatic Cancer Undergoing First-Line Chemotherapy with FOLFIRINOX or Gemcitabine/nab-Paclitaxel
    Riedl, Jakob M.
    Schwarzenbacher, Esther
    Moik, Florian
    Horvath, Lena
    Gantschnigg, Antonia
    Renneberg, Felix
    Posch, Florian
    Barth, Dominik A.
    Stotz, Michael
    Pichler, Martin
    Hatzl, Stefan
    Fandler-Hofler, Simon
    Gressenberger, Paul
    Gary, Thomas
    Jost, Philipp J.
    Greil, Richard
    Ay, Cihan
    Djanani, Angela
    Gerger, Armin
    Schlick, Konstantin
    THROMBOSIS AND HAEMOSTASIS, 2022, 122 (04) : 633 - 645
  • [36] Erlotinib, gemcitabine, paclitaxel and radiation for locally advanced pancreatic cancer: A phase I study.
    Iannitti, D
    Dipetrillo, T
    Cruff, D
    Sambandam, S
    Maia, C
    Hughes, M
    Oldenburg, N
    Thornton, K
    Kennedy, T
    Safran, H
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 336S - 336S
  • [37] Gemcitabine confirmed as the first-line therapy for pancreatic cancer
    Claire Greenhill
    Nature Reviews Gastroenterology & Hepatology, 2011, 8 (1) : 3 - 3
  • [38] Efficacy of nimotuzumab plus gemcitabine usage as first-line treatment in patients with advanced pancreatic cancer
    Su, Dan
    Jiao, Shun-Chang
    Wang, Li-Jie
    Shi, Wei-Wei
    Long, Yan-Yan
    Li, Juan
    Bai, Li
    TUMOR BIOLOGY, 2014, 35 (03) : 2313 - 2318
  • [39] Clinical benefit with gemcitabine (GEM) as first-line therapy for patients with advanced pancreatic cancer (APC)
    Manzano, H
    Esquerdo, G
    Rifa, J
    Aguiar, D
    Arrivi, A
    Pazo, R
    Martin, J
    Terrasa, J
    ANNALS OF ONCOLOGY, 1998, 9 : 54 - 54
  • [40] Immunomodulatory effects of lenalidomide in combination with gemcitabine as first-line treatment in patients with advanced pancreatic cancer
    Liljefors, M.
    Mozaffari, F. S.
    Mellstedt, H.
    Ullenhag, G.
    ANNALS OF ONCOLOGY, 2015, 26 : 12 - 12
12345